Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Boston Scientific Corporation
University of Florida
Jonsson Comprehensive Cancer Center
Chimeric Therapeutics
SAPU NANO (US) LLC
Barbara Ann Karmanos Cancer Institute
University of Nebraska
Guerbet
RayzeBio, Inc.
IRCCS San Raffaele
Imperial College London
University Hospital, Strasbourg, France
University of Iowa
ITM Solucin GmbH
Tanabe Pharma America, Inc.
Nantes University Hospital
Perspective Therapeutics
Massive Bio, Inc.
Advanced Accelerator Applications
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Cook Group Incorporated
ITM Solucin GmbH
RayzeBio, Inc.
Barbara Ann Karmanos Cancer Institute
Jonsson Comprehensive Cancer Center
Turning Point Therapeutics, Inc.
University of Pittsburgh
PharmaMar
Nuvation Bio Inc.
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Abramson Cancer Center at Penn Medicine
Hutchmed
Case Comprehensive Cancer Center
IRCCS San Raffaele
Nanjing First Hospital, Nanjing Medical University
UNICANCER
Second Affiliated Hospital, School of Medicine, Zhejiang University
Grupo Espanol de Tumores Neuroendocrinos
Western Sydney Local Health District
Advanced Accelerator Applications
Grupo Espanol de Tumores Neuroendocrinos
University of Sao Paulo
Teclison Ltd.